University of Arizona College of Medicine - Phoenix ABC-1 Building 425 North 5th Street, Phoenix, AZ 85004
Associate Professor - Basic Medical Sciences
Basic Medical Sciences
- Postdoctoral Fellowship: Immunobiology, Yale University, Howard Hughes Medical Institute, 2006
- Residency: Dermatology, Yale New Haven Hospital, 2004
- Internship: Internal Medicine, Yale New Haven Hospital, 2001
- MD: Harvard University, 2000
- PhD: Immunology, Harvard University, 2000
- American Board of Dermatology
Representative Recent Publications
- Rausch MP, Meador LR, Metzger TC, Li H, Qiu S, Anderson MS & Hastings KT (2020). GILT in thymic epithelial cells facilitates central CD4 T cell tolerance to a tissue-restricted, melanoma-associated self antigen. J Immunol. Vol. 204(11), 2877-2886.
- Borden ES, Kang P, Natri HM, Phung TN, Wilson MA, Buetow KH & Hastings KT (2019). Neoantigen fitness model predicts lower immune recognition of cutaneous squamous cell carcinomas than actinic keratoses. Front Immunol. Vol. 10, 2799.
- Buetow KH, Meador LR, Menon H, Lu YK, Brill J, Cui H, Roe DJ, DiCaudo DJ & Hastings KT (2019). High GILT expression and an active and intact MHC class II antigen presentation pathway are associated with improved survival in melanoma. J Immunol. Vol. 203(10), 2577-2587.
- Rausch MP & Hastings KT (2017). Immune checkpoint inhibitors in the treatment of melanoma: from basic science to clinical application; In textbook of Cutaneous Melanoma: Etiology and Therapy - Ward, WH, Farma, JM, eds.. (pp. Chapter 9). Codon Publications, Brisbane, Australia.
- Nguyen J, Bernert R, In K, Kang P, Sebastiao N, Hu C & Hastings KT (2016). Gamma-interferon-inducible lysosomal thiol reductase is upregulated in human melanoma. Melanoma Res. Vol. 26(2), 125-37.
Skin Cancer, Neoplasms, Squamous Cell, Melanoma, Immunology, Development and Regulation of Immune Responses, Dermatology, Carcinoma, Cancer, Autoimmunity, Antigen Presentation
Dr. Hastings is a physician-scientist with a research program focused on antigen processing and control of T cell responses in skin cancer and autoimmunity. Her laboratory has defined gamma-interferon-inducible lysosomal thiol reductase (GILT) as a critical enzyme in MHC class II-restricted presentation of and regulation of T cell tolerance to melanocyte differentiation antigens important in melanoma and vitiligo. She is investigating the clinical significance of GILT in melanoma and lymphoma.